EMEA-003184-PIP01-22
Submitted by Anonymous (not verified) on 7 June 2024 - 16:17
EMEA-003184-PIP01-22
Agenda - Joint HMA/EMA Big Data Steering Group workshop on real-world evidence (RWE) methods
Submitted by Anonymous (not verified) on 7 June 2024 - 15:57
Agenda - Joint HMA/EMA Big Data Steering Group workshop on real-world evidence (RWE) methods
EMEA-003080-PIP03-22
Submitted by Anonymous (not verified) on 7 June 2024 - 15:38
EMEA-003080-PIP03-22
Change management activities delivery plan
Submitted by Anonymous (not verified) on 7 June 2024 - 14:34
Change management activities delivery plan
Workplan 2023-2025: HMA-EMA joint Big Data Steering Group
Submitted by Anonymous (not verified) on 7 June 2024 - 14:15
Workplan 2023-2025: HMA-EMA joint Big Data Steering Group
EMEA-002612-PIP02-22
Submitted by Anonymous (not verified) on 7 June 2024 - 14:08
EMEA-002612-PIP02-22
Opinion/decision on a Paediatric investigation plan (PIP): Evusheld, tixagevimab,cilgavimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Infectious diseases, PIP numb
Submitted by Anonymous (not verified) on 7 June 2024 - 14:03
Opinion/decision on a Paediatric investigation plan (PIP): Evusheld, tixagevimab,cilgavimab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Infectious diseases, PIP number: P/0119/2023
Orphan designation: Sorafenib tosilate Treatment of papillary thyroid cancer, 13/11/2013 Expired
Submitted by Anonymous (not verified) on 7 June 2024 - 13:58
Orphan designation: Sorafenib tosilate Treatment of papillary thyroid cancer, 13/11/2013 Expired
Orphan designation: Sorafenib tosilate Treatment of follicular thyroid cancer, 13/11/2013 Expired
Submitted by Anonymous (not verified) on 7 June 2024 - 13:58
Orphan designation: Sorafenib tosilate Treatment of follicular thyroid cancer, 13/11/2013 Expired
Orphan designation: Chimeric anti-interleukin-6 monoclonal antibody (siltuximab) Treatment of Castleman's disease, 30/11/2007 Expired
Submitted by Anonymous (not verified) on 7 June 2024 - 13:56
Orphan designation: Chimeric anti-interleukin-6 monoclonal antibody (siltuximab) Treatment of Castleman's disease, 30/11/2007 Expired